An increased HLA DR2 frequency is seen in aplastic anemia patients

Stephen D Nimer, Priscilla Ireland, Azin Meshkinpour, Margaret Frane

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The underlying etiology of aplastic anemia is unknown in the majority of patients, although medications, chemical exposure, or viral infections can be implicated in some. Genetic susceptibility to a variety of diseases has been shown and it has recently been suggested that aplastic anemia is more common in individuals who are HLA DR2+ than in the general population. To examine this question, we retrospectively analyzed the results of HLA-DR typing in 75 aplastic anemia patients who received antithymocyte globulin (ATG) therapy or an HLA-matched sibling bone marrow transplant at UCLA between 1978 and 1989. Thirty-one patients were DR2+, a 1.9-fold higher incidence than the expected number of 16.6 patients (P < .0005). Of the 37 patients who received ATG, 33 were evaluable for a response; 14 patients had either a complete (4 patients) or partial (10 patients) response, for an overall response rate of 42.4%. Of the 14 DR2+ patients who received ATG, 7 responded, for a 50% response rate, which is not significantly higher than the response rate for the DR2- patients (7 of 19 [36.8%]; P = .50). The median survival of patients who are DR2+ was slightly, but not significantly, longer than that of the DR2- patients in the ATG group (P = .19). Although the incidence of HLA DR2 was clearly increased in these patients with aplastic anemia, response rates to ATG were not significantly different in the DR2+ and DR2- patients.

Original languageEnglish
Pages (from-to)923-927
Number of pages5
JournalBlood
Volume84
Issue number3
StatePublished - Aug 1 1994
Externally publishedYes

Fingerprint

HLA-DR2 Antigen
Antilymphocyte Serum
Aplastic Anemia
Transplants
HLA-DR Antigens
Bone
Histocompatibility Testing
Incidence
Virus Diseases

ASJC Scopus subject areas

  • Hematology

Cite this

Nimer, S. D., Ireland, P., Meshkinpour, A., & Frane, M. (1994). An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood, 84(3), 923-927.

An increased HLA DR2 frequency is seen in aplastic anemia patients. / Nimer, Stephen D; Ireland, Priscilla; Meshkinpour, Azin; Frane, Margaret.

In: Blood, Vol. 84, No. 3, 01.08.1994, p. 923-927.

Research output: Contribution to journalArticle

Nimer, SD, Ireland, P, Meshkinpour, A & Frane, M 1994, 'An increased HLA DR2 frequency is seen in aplastic anemia patients', Blood, vol. 84, no. 3, pp. 923-927.
Nimer SD, Ireland P, Meshkinpour A, Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 1994 Aug 1;84(3):923-927.
Nimer, Stephen D ; Ireland, Priscilla ; Meshkinpour, Azin ; Frane, Margaret. / An increased HLA DR2 frequency is seen in aplastic anemia patients. In: Blood. 1994 ; Vol. 84, No. 3. pp. 923-927.
@article{6a78db0b550b4bdc9af6944e8595621a,
title = "An increased HLA DR2 frequency is seen in aplastic anemia patients",
abstract = "The underlying etiology of aplastic anemia is unknown in the majority of patients, although medications, chemical exposure, or viral infections can be implicated in some. Genetic susceptibility to a variety of diseases has been shown and it has recently been suggested that aplastic anemia is more common in individuals who are HLA DR2+ than in the general population. To examine this question, we retrospectively analyzed the results of HLA-DR typing in 75 aplastic anemia patients who received antithymocyte globulin (ATG) therapy or an HLA-matched sibling bone marrow transplant at UCLA between 1978 and 1989. Thirty-one patients were DR2+, a 1.9-fold higher incidence than the expected number of 16.6 patients (P < .0005). Of the 37 patients who received ATG, 33 were evaluable for a response; 14 patients had either a complete (4 patients) or partial (10 patients) response, for an overall response rate of 42.4{\%}. Of the 14 DR2+ patients who received ATG, 7 responded, for a 50{\%} response rate, which is not significantly higher than the response rate for the DR2- patients (7 of 19 [36.8{\%}]; P = .50). The median survival of patients who are DR2+ was slightly, but not significantly, longer than that of the DR2- patients in the ATG group (P = .19). Although the incidence of HLA DR2 was clearly increased in these patients with aplastic anemia, response rates to ATG were not significantly different in the DR2+ and DR2- patients.",
author = "Nimer, {Stephen D} and Priscilla Ireland and Azin Meshkinpour and Margaret Frane",
year = "1994",
month = "8",
day = "1",
language = "English",
volume = "84",
pages = "923--927",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - An increased HLA DR2 frequency is seen in aplastic anemia patients

AU - Nimer, Stephen D

AU - Ireland, Priscilla

AU - Meshkinpour, Azin

AU - Frane, Margaret

PY - 1994/8/1

Y1 - 1994/8/1

N2 - The underlying etiology of aplastic anemia is unknown in the majority of patients, although medications, chemical exposure, or viral infections can be implicated in some. Genetic susceptibility to a variety of diseases has been shown and it has recently been suggested that aplastic anemia is more common in individuals who are HLA DR2+ than in the general population. To examine this question, we retrospectively analyzed the results of HLA-DR typing in 75 aplastic anemia patients who received antithymocyte globulin (ATG) therapy or an HLA-matched sibling bone marrow transplant at UCLA between 1978 and 1989. Thirty-one patients were DR2+, a 1.9-fold higher incidence than the expected number of 16.6 patients (P < .0005). Of the 37 patients who received ATG, 33 were evaluable for a response; 14 patients had either a complete (4 patients) or partial (10 patients) response, for an overall response rate of 42.4%. Of the 14 DR2+ patients who received ATG, 7 responded, for a 50% response rate, which is not significantly higher than the response rate for the DR2- patients (7 of 19 [36.8%]; P = .50). The median survival of patients who are DR2+ was slightly, but not significantly, longer than that of the DR2- patients in the ATG group (P = .19). Although the incidence of HLA DR2 was clearly increased in these patients with aplastic anemia, response rates to ATG were not significantly different in the DR2+ and DR2- patients.

AB - The underlying etiology of aplastic anemia is unknown in the majority of patients, although medications, chemical exposure, or viral infections can be implicated in some. Genetic susceptibility to a variety of diseases has been shown and it has recently been suggested that aplastic anemia is more common in individuals who are HLA DR2+ than in the general population. To examine this question, we retrospectively analyzed the results of HLA-DR typing in 75 aplastic anemia patients who received antithymocyte globulin (ATG) therapy or an HLA-matched sibling bone marrow transplant at UCLA between 1978 and 1989. Thirty-one patients were DR2+, a 1.9-fold higher incidence than the expected number of 16.6 patients (P < .0005). Of the 37 patients who received ATG, 33 were evaluable for a response; 14 patients had either a complete (4 patients) or partial (10 patients) response, for an overall response rate of 42.4%. Of the 14 DR2+ patients who received ATG, 7 responded, for a 50% response rate, which is not significantly higher than the response rate for the DR2- patients (7 of 19 [36.8%]; P = .50). The median survival of patients who are DR2+ was slightly, but not significantly, longer than that of the DR2- patients in the ATG group (P = .19). Although the incidence of HLA DR2 was clearly increased in these patients with aplastic anemia, response rates to ATG were not significantly different in the DR2+ and DR2- patients.

UR - http://www.scopus.com/inward/record.url?scp=0028335812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028335812&partnerID=8YFLogxK

M3 - Article

C2 - 8043874

AN - SCOPUS:0028335812

VL - 84

SP - 923

EP - 927

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -